Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NCP101 is a synthetic hexameric peptide developed by NovaCell Technology for cosmetic applications, specifically targeting wrinkle improvement and skin whitening. It functions as a G protein-coupled receptor (GPCR) ligand and interacts with the Vascular Endothelial Growth Factor A (VEGFA) and Vascular Endothelial Growth Factor Receptor 1 (VEGFR1) signaling pathways. Developed using the proprietary PS-SPCL peptide library platform, NCP101 has been registered as a cosmetic ingredient and has completed clinical testing for safety and efficacy in dermatological applications. It is also being explored for potential wound healing properties.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on NCP101.